α-bisabolol-loaded lipid-core nanocapsules reduce lipopolysaccharide-induced pulmonary inflammation in mice

Abstract

Acute respiratory distress syndrome (ARDS) is a severe clinical condition of respiratory failure due to an intense inflammatory response with different etiologies. Despite all efforts, therapy remains limited, and ARDS is still associated with high mortality and morbidity. Plants can provide a vast source of active natural products for the discovery of new drugs. α-bisabolol (α-bis), a constituent of the essential oil from chamomile, has elicited pharmacological interest. However, the molecule has some limitations to its biological application. This study was conducted to develop a drug delivery system using lipid-core nanocapsules (LNCs) to improve the anti-inflammatory effects of orally administered α-bis. α-bis-loaded LNCs (α-bis-LNCs) were prepared by interfacial deposition of poly(ε-caprolactone) and orally administered in a mouse model of ARDS triggered by an intranasal administration of lipopolysaccharide (LPS). We found that α-bis-LNCs (30, 50, and 100 mg kg −1 ) significantly reduced airway hyperreactivity (AHR), neutrophil infiltration, myeloperoxidase activity, chemokine levels (KC and MIP-2), and tissue lung injury 18 hours after the LPS challenge. By contrast, free α-bis failed to modify AHR and neutrophil accumulation in the bronchoalveolar lavage effluent and lung parenchyma and inhibited elevation in the myeloperoxidase and MIP-2 levels only at the highest dose. Furthermore, only α-bis-LNCs reduced LPS-induced changes in mitogen-activated protein kinase signaling, as observed by a significant reduction in phosphorylation levels of ERK1/2, JNK, and p38 proteins. Taken together, our results clearly show that by using LNCs, α-bis was able to decrease LPS-induced inflammation. These findings may be explained by the robust increase of α-bis concentration in the lung tissue that was achieved by the LNCs. Altogether, these results indicate that α-bis-LNCs should further be investigated as a potential alternative for the treatment of ARDS.

Low‐dose curcumin‐loaded Eudragit L‐100‐nanocapsules in the diet of dairy sheep increases antioxidant levels and reduces lipid peroxidation in milk

“…They are one of the most studied release systems nanostructured that can protect against degradation processes, increase the solubility and potentiate the biological absorption of the active, besides allowing a controlled release (Mora‐Huertas, Fessi, & Elaissari, ). D'Almeida et al () developed α‐bisabolol nanocapsules also by the interfacial deposition of the preformed polymer method and obtained an average size around 160 nm, a polydispersity index of 0.1, negative zeta potential, acidic pH, and encapsulation efficiency around 100%, corroborating with the results obtained in the present study (D'Almeida et al, ).…”

Oleic acid-based nanosystems for mitigating acute respiratory distress syndrome in mice through neutrophil suppression: how the particulate size affects therapeutic efficiency

“…The lung accumulation of the OA nanoparticles was size-dependent, with the larger sizes exhibiting greater uptake. The nanoparticles even with a large diameter can enter the lung tissue since the pulmonary epithelium in ARDS reveals an elevated microvascular permeability [46]. Dysfunction of the epithelial barrier facilitates the diffusion of macromolecules and nanoparticles into the alveolar space.…”

Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge

“…LPS acts on Toll-like receptor 4 to promote cytokines in the lung, resulting in neutrophil infiltration, hemorrhage, and alveolar disruption [ 21 ]. The cytokines are early biomarkers that respond in ALI.…”